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Safetya b s t r a c t
Many countries recommend combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
immunization (Tdap) during pregnancy to stimulate transplacental transmission of pertussis antibodies
to newborns. The immune system can be altered during pregnancy, potentially resulting in differing immu-
nization risks in pregnantwomen. The safety ofwidespread Tdap immunization during pregnancy needs to
be established. Our objective was to assess whether prenatal Tdap immunization was associated with
adverse birth outcomes, and to evaluate the effect of timing of Tdap administration on these outcomes.
We identified pregnancies at delivery in a large insurance claims database (2010–2014). Tdap immu-
nization was categorized as optimal prenatal (27 + weeks), early prenatal (<27 weeks), postpartum
(7 days post-delivery), or none.Medical claimswere searched to identifymaternal adverse immunization
reactions (e.g. anaphylaxis, fever, Guillian-Barre syndrome [GBS]), adverse birth outcomes (e.g. preeclamp-
sia/eclampsia, premature rupture or membranes, chorioamnionitis) and newborn outcomes (e.g. respira-
tory distress, pulmonary hypertension, neonatal jaundice). Women with optimal or early prenatal Tdap
were compared to those not immunized in pregnancy, using propensity score-weighted log-binomial
regression and Cox proportional hazards models to estimate risk ratios (RR) and hazard ratios (HR). We
identified 1,079,034 deliveries and 677,075 linked newborns; 11.5% were immunized optimally and
2.3% immunized early. There were 1 case of post-immunization anaphylaxis, and 12 cases of maternal
encephalopathy (all post- delivery); there were no cases of GBS. Optimally-timed immunization was asso-
ciated with small increased relative risks of: chorioamnionitis [RR = 1.11, (95% CI: 1.07–1.15), overall
risk = 2.8%], and postpartum hemorrhage [RR = 1.23 (95% DI: 1.18–1.28), overall risk = 2.4%]; however,
these relative increases corresponded to low absolute risk increases. Tdap was not associated with
increased risk of any adverse newborn outcome. Overall, prenatal Tdap immunization was not associated
with newborn adverse events, but potential associations with chorioamnionitis consistent with one previ-
ous study and postpartum hemorrhage require further investigation.1. Introduction mission of maternal pertussis antibodies [1–6]; thus, several coun-Tetanus toxoid, reduced diphtheria toxoid and acellular pertus-
sis immunization (Tdap) administered during pregnancy conveys
passive pertussis immunity to newborns via transplacental trans-tries recommend Tdap during every pregnancy, including closely
spaced pregnancies [7–9]. Despite international efforts to prevent
infant pertussis through maternal Tdap, prenatal uptake remains
sub-optimal [10–14], due in part to concerns about safety
[15,16]. While generally accepted as safe, widespread prenatal
Tdap requires careful scrutiny to establish the safety for the
mother and newborn.
Fig. 1. Schematic showing Tdap immunization timing by delivering women and
linked newborns.Tdap has not been associated with clinically significant harms
for the fetus or neonate such as preterm birth, small for gestational
age, stillbirth, low birth weight, or congenital anomalies [17]. Sim-
ilarly, there is no evidence of increased risk of serious adverse
events in pregnancy, with the exception of unreplicated findings
of increased chorioamnionitis risk from one retrospective study
[17,18]. Previous non-experimental studies have been limited by
small sample size, unclear immunization timing, and confounding
due to comparing guideline-adherent immunized versus non-
adherent unimmunized populations. Given that a strong under-
standing of the safety of Tdap during pregnancy may be central
to increasing uptake, additional studies are needed.
Furthermore, considerable uncertainty persists about the opti-
mal timing of prenatal Tdap administration. The CDC recommends
administration at any time during pregnancy, though preferably
between gestational weeks 27–36 [19] to maximize maternal anti-
body response and passive antibody transfer; other countries rec-
ommend administration during the second [8] or third trimesters
[9] to improve immunization coverage for preterm deliveries.
Safety studies which account for the timing of immunization are
limited [17].
To examine the safety of Tdap administration during pregnancy,
we conducted a large-scale, cohort study comparing the risks of
adverse outcomes in the infant and mother associated with Tdap
and examined the impact of timing of Tdap administration on
safety.2. Methods
This administrative insurance claims-based cohort study was
approved by the Institutional Review Board of the University of
North Carolina at Chapel Hill. Analyses were performed using
SAS 9.4 (SAS Institute, Cary NC).
2.1. Data source
We utilized the MarketScan Commercial Claims and Encounters
(Truven Health Analytics) insurance claims databases for the years
2010–2014which spanned CDC’s changing Tdap recommendations.
These databases contain individual-level health insurance enroll-
ment and billing information, including inpatient and outpatient
procedures and diagnoses, and pharmacy-dispensed medications
for those with employer-based commercial insurance, spouses,
and dependents for tens of millions of enrollees across the U.S.
2.2. Study population
We identified females with livebirth or stillbirth deliveries
using International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) diagnosis codes (ICD-9-CM V27). Where
possible, we linked mothers to offspring by identifying newborns
within the same insurance plan family grouping with birth coding
(ICD-9-CM codes V30-V37) within 7 days of the mother’s delivery
code to account for slight differences in billing and enrollment tim-
ing between the mother and child [14,20,21]; linkage was not pos-
sible if the mothers and newborns were covered by different
insurance plans. We estimated gestational age at delivery by
imputing standard ages based on delivery prematurity or post-
term delivery diagnoses codes from the mother and linked child
[22–24]. To capture complete prenatal and postpartum immuniza-
tion and clinical information, we required continuous health plan
enrollment from the estimated onset of pregnancy to seven days
post-delivery (Fig. 1).
We included only the first observed pregnancy per woman, and
excluded pregnancies with twins or multiples due to increasedcomplication risk and hindered ability to accurately estimate ges-
tational age. We excluded women with estimated gestational ages
at delivery 26 weeks as the CDC recommendation for optimal
Tdap is at 27+ weeks. We also excluded women 18 years in 13
states with universal childhood immunization policies,[25] as
immunization claims would be unavailable.
2.3. Tdap exposure
We searched insurance claims from pregnancy onset to 7 days
post-delivery for Tdap administration using billing procedure
codes (Current Procedural Terminology [CPT] code 90715, or ICD-
9-CM procedure codes, 99.37, 99.39, V06.1). Tdap timing was cat-
egorized as optimal (27 weeks gestational age according to the
2012 CDC recommendation), early (prior to 27 weeks), or postpar-
tum (from delivery to 7 days afterward) (Fig. 1).
2.4. Maternal and newborn characteristics
We identified clinical and demographic characteristics of
women and newborns to account for confounding by differences
between Tdap groups using insurance enrollment data and diagno-
sis or procedure claims. Maternal demographic characteristics
were assessed at estimated pregnancy onset and included: age;
U.S. geographic region; residence in a metropolitan statistical area
(MSA) as a marker of urbanicity; other covered children on health
plan; and delivery year. Clinical characteristics assessed from con-
ception to 140 days gestational age included: markers of compli-
cated pregnancies, such as maternal hospitalizations and
emergency department visits; health care utilization, including
prenatal blood panel and ultrasound receipt. Maternal comorbidi-
ties assessed from conception to delivery included hypertension,
diabetes, gestational diabetes, kidney dysfunction, lupus, and use
of antihypertensive, antidiabetic agents, antidepressants, or antibi-
otics. Newborn characteristics assessed at delivery included: sex,
premature or post-dates birth, maternal preeclampsia/eclampsia,
delivery by cesarean section, and meconium aspiration.
2.5. Outcomes and analysis
We considered 3 categories of safety outcomes: maternal
adverse immunization reactions, maternal birth outcomes, and
newborn outcomes.
2.5.1. Maternal adverse immunization reactions
Among immunized women, we evaluated adverse reactions fol-
lowing prenatal or postpartum Tdap administration. We searched
claims post-immunization for: 2 days for anaphylaxis; 3 days for
fever [26]; 7 days for cellulitis, and pain in limb [26,27]; and
42 days for encephalopathy [26] and Guillan-Barre syndrome
(GBS) [26,27], We considered either inpatient or outpatient diag-
noses of all outcomes except for encephalopathy (which required
an inpatient diagnosis) and GBS (which required a diagnosis in
the primary position [28]) to ensure accurate identification of
cases. To ensure identification of new-onset cases, those experienc-
ing encephalopathy or GBS at any time from conception to immu-
nization, or the other acute outcomes in the 7 days prior to
immunization were excluded.
We reported counts and risks of post-immunization events.
Women were censored due to disenrollment from the insurance
plan. Given substantial increase in healthcare utilization and other
medical events occurring immediately post-partum, we did not
directly compare the pre- and post-partum periods.
2.5.2. Maternal birth outcomes
Among all delivering women, insurance records were searched
for pregnancy complications identified by diagnoses or procedures
(eTable 1). Various time windows before, during, or after delivery
were searched depending on the outcome: placental abruption,
premature rupture of membranes, and caesarian section were
identified on the delivery date; chorioamnionitis was identified
during the delivery hospitalization; post-partum hemorrhage was
identified from the delivery date through seven days post-
delivery; preeclampsia/eclampsia was identified from seven days
pre-delivery through 30 days post-delivery. We separately com-
pared women with optimally-timed and early Tdap to those not
immunized prior to delivery with multivariable log-binomial mod-
els to estimate adjusted risk ratios (RR) and 95% confidence inter-
vals (CI). Models were adjusted for a priori identified maternal
demographics and clinical characteristics. Propensity score (PS)
methods were also used to control for confounding. A PS for Tdap
receipt was estimated with logistic regression using maternal char-
acteristics and was then transformed into stabilized inverse-
probability of treatment weights (IPTW). The analysis was
repeated in an IPTW-weighted population to estimate the average
treatment effect in the population [29,30]. We trimmed individuals
with PS below the 0.5th and above the 99.5th percentiles of the PS
distributions to reduce the influence of confounding concentrated
in the tails of the PS distribution [31]. IPTW results are presented
as our primary results, with multivariable adjusted models also
presented for comparison.
Since preeclampsia/eclampsia required the longest follow-up
(30 days post-delivery), we compared immunization groups with
Cox proportional hazards models allowing for censoring due to
health plan disenrollment, and estimated hazard ratios (HR) and
95% CI with follow-up beginning 7 days before delivery. The pro-
portional hazards assumption for all Cox models was tested for
all cox models by plotting Kaplan-Meier curves.
2.5.3. Newborn outcomes
In the linked maternal-newborn pairs, we followed newborns
for up to 30 days post-delivery for neonatal intensive care unit
(NICU) admissions, respiratory distress, pulmonary hypertension,
inpatient encephalopathy, seizures, neonatal sepsis, and inpatient
neonatal jaundice. Follow-up began at delivery, and newborns
could be censored due to health plan disenrollment. We estimated
IPTW-weighted HRs and 95% CIs for newborns with optimally- or
early-immunized mothers compared with newborns whose moth-
ers were not vaccinated during pregnancy adjusted for maternal
and newborn characteristics.
2.6. Sensitivity analyses
As there may be misclassification of ‘‘early” and ‘‘optimal” tim-
ing categorizations, we evaluated any Tdap in pregnancy without
respect to timing. To reduce confounding by differences in health-
care access, behaviors, and attitudes between immunization recei-
vers and non-receivers,[32–34] we repeated all analyses restrictingthe cohort to women who received influenza immunization during
pregnancy.3. Results
We identified 1,079,034 women (mean age = 29.2 years, SD
5.4 years) with deliveries meeting our study criteria (eFig. 1). Of
these women, 148,817 (13.8%) received Tdap during pregnancy,
and an additional 59,040 (5.5%) women received Tdap postpartum.
The percentage of pregnant women receiving Tdap increased over
time; cohort characteristics are shown in Table 1.
3.1. Maternal adverse immunization reactions
Among the 207,857 women receiving Tdap, the most common
medically-attended adverse reactions experienced were pain in
limb or fever (Table 2, eTable 2 for rates). 2% of women were cen-
sored before the full 42-day follow up for GBS, yet no cases of inpa-
tient GBS were observed. Other serious adverse reactions
experienced after immunization were very rare, with only a very
small number of cases occurring in the entire sample; there was
1 case of anaphylaxis in a woman vaccinated postpartum, and 7
encephalopathy cases occurred in women vaccinated prenatally,
but in all 7 cases, the 42-day follow-up overlapped the delivery,
and the encephalopathy occurred during the delivery hospitaliza-
tion or after.
Adverse reaction risks tended to be higher for those vaccinated
postpartum and early prenatal periods (Table 2), but it was difficult
to disentangle the effects of an immunization from other medical
conditions experienced in the delivery and postpartum period in
a setting characterized by increased contact from the healthcare
providers during this time; consequently, we did not make direct
comparisons between the postpartum and prenatal periods.
3.2. Maternal birth outcomes
In the 1,079,034 women, the IPTW-weighted population
resulted in good balance between covariates (eTables 3–4). The
risks of many birth outcomes were similar between those who
did and did not receive Tdap during pregnancy (see Table 3). How-
ever, optimally-timed Tdap was associated with a small increase in
chorioamnionitis [IPTW-weighted risks: 3.3% optimally immu-
nized women, 3.0% unimmunized women; RR = 1.11 (95% CI:
1.07–1.15)] and post-partum hemorrhage [IPTW-weighted risks:
2.9% optimally immunized women, 2.4% unimmunized women;
RR = 1.23 (95% CI: 1.18–1.28), as compared to women who did
not receive Tdap during pregnancy. Early Tdap receipt was also
associated with chorioamnionitis [IPTW-weighted risks: 3.6% in
early immunized women, 2.8% in unimmunized women;
RR = 1.19 (95% CI: 1.11–1.28)], and post-partum hemorrhage,
[IPTW-weighted risks: 3.13% early immunized women, 2.3% unim-
munized women; RR = 1.34 (95% CI: 1.25–1.44)], and additionally
with premature rupture of membranes [IPTW-weighted risks:
5.2% in early immunized women, 4.9% in unimmunized women;
RR = 1.08 (95% CI: 1.02–1.15)]. 4% of women were censored before
the full 30-day post-delivery follow-up for eclampsia.
3.3. Newborn outcomes
Of all the delivering women, 677,075 (62.8%) successfully
matched to a newborn. The distributions of baseline characteristics
among mothers who successfully matched to a newborn were very
similar to the overall sample, but matching mothers had slightly
more routine preventive care (eTable 5–6). 4% of newborns were
censored before the end of the 30-day post-delivery follow-up.
Table 1











Age, mean (SD) 29.2 5.4 29.6 5.1 29.4 5.2 28.9 5.3 29.2 5.4
Year
2010 n,% 182,828 16.9 1189 1.0 462 1.9 5942 10.1 175,235 20.1
2011 n,% 236,606 21.9 2512 2.0 2673 10.7 14,906 25.3 216,515 24.9
2012 n,% 254,731 23.6 12,094 9.8 4963 19.8 17,630 29.9 220,044 25.3
2013 n,% 188,043 17.4 34,714 28.0 7610 30.4 10,342 17.5 135,377 15.5
2014 n,% 216,826 20.1 73,271 59.2 9329 37.3 10,220 17.3 124,006 14.2
Preterm birth n,% 79,677 7.4 6154 5.0 2593 10.4 3962 6.7 66,968 7.7
Other covered children on plan, mean (SD) 1.6 1.2 1.5 1.1 1.5 1.1 1.6 1.1 1.7 1.2
Received obstetric blood panel* n,% 587,342 54.4 68,887 55.7 14,168 56.6 35,906 60.8 468,381 53.8
Received ultrasound* n,% 853,745 79.1 109,157 88.2 22,517 89.9 48,400 82.0 673,671 77.3
Received flu immunization n,% 239,593 22.2 59,932 48.4 12,919 51.6 12,384 21.0 154,358 17.7
Hospitalizations, mean (SD)* 0.01 0.01 0.01 0.09 0.01 0.11 0.01 0.11 0.01 0.11
Emergency department visits, mean (SD)* 0.21 0.67 0.19 0.61 0.22 0.71 0.22 0.67 0.21 0.67
Lives in MSA n,% 917,056 85.0 107,713 87.0 21,784 87.0 50,285 85.2 737,274 84.6
Missing n,% 28,150 2.6 3942 3.2 796 3.2 1573 2.7 21,839 2.5
Region
Northeast n,% 169,749 15.7 19,300 15.6 3634 14.5 7943 13.5 138,872 15.9
Midwest n,% 257,559 23.9 32,881 26.6 5790 23.1 12,951 21.9 205,937 23.6
South n,% 392,581 36.4 35,264 28.5 6509 26.0 23,531 39.9 327,277 37.6
West n,% 230,952 21.4 32,392 26.2 8308 33.2 13,041 22.1 177,211 20.3
Unknown n,% 28,193 2.6 3943 3.2 796 3.2 1574 2.7 21,880 2.5
Maternal hypertension n,% 151,135 14.0 17,927 14.5 3489 13.9 8070 13.7 121,649 14.0
Diabetes mellitus n,% 19,751 1.8 2060 1.7 411 1.6 952 1.6 16,328 1.9
Gestational Diabetes n,% 152,059 14.1 18,372 14.8 3533 14.1 8461 14.3 121,693 14.0
Kidney dysfunction n,% 2203 0.2 266 0.2 52 0.2 75 0.1 1810 0.2
Lupus n,% 2415 0.2 271 0.2 64 0.3 104 0.2 1976 0.2
Antihypertensive use n,% 36,684 3.4 3631 2.9 769 3.1 1902 3.2 30,382 3.5
Antidiabetic use n,% 30,485 2.8 4262 3.4 850 3.4 1469 2.5 23,904 2.7
SSRI use n,% 34,674 3.2 4749 3.8 919 3.7 1774 3.0 27,232 3.1
Antibiotic use n,% 298,282 27.6 34,519 27.9 6927 27.7 17,050 28.9 239,786 27.5
Matched to baby n,% 677,075 62.8 80,217 64.8 16,322 65.2 36,630 62.0 543,906 62.4
Abbreviations: Tdap, tetanus-diphteria-acellular pertussis immunization; SD, standard deviation; MSA, metropolitan statistical area; SSRI, serotonin selective reuptake
inhibitor.
* Assessed from pregnancy onset to 20 weeks.
Table 2
Adverse immunization reactions by timing of pertussis immunization among pregnant and delivering women in the US, 2010–2014.
Outcome Follow-up length post-immunization Immunization timing Total N Cases Unadjusted Risks (per 10,000 women)
Anaphylaxis 2 days Total 207,851 1 0.00
Early 25,035 0 0.00
Optimal 123,780 0 0.00
Postpartum 59,038 1 0.17
Fever 3 days Total 207,821 129 6.2
Early 25,033 13 5.19
Optimal 123,760 47 3.80
Postpartum 59,028 69 11.69
Cellulitis 7 days Total 207,822 122 5.87
Early 25,030 43 17.18
Optimal 123,763 27 2.18
Postpartum 59,029 52 8.81
Pain in limb 7 days Total 207,663 503 24.22
Early 25,001 92 36.80
Optimal 123,441 217 17.58
Postpartum 59,004 194 32.88
Encephalopathy 42 days Total 207,853 12 0.58
Early 25,037 0 0.00
Optimal 123,777 7 0.57
Postpartum 59,039 5 0.85
Guillain-Barré Syndrome 42 days Total 207,857 0 0.00
Early 25,037 0 0.00
Optimal 123,780 0 0.00
Postpartum 59,040 0 0.00Some newborn events were quite common (e.g. NICU admission,
respiratory distress, and neonatal jaundice all had incidence >6%).
The proportional hazards assumptions were met for all models,
but optimally-timed or early prenatal Tdap were not associated
with increased risks for any outcome compared to non-receivers
(Table 4).3.4. Sensitivity analysis
When evaluating any Tdap immunization during pregnancy
without regards to the timing, the overall results were consistent
with the optimal and early timing results (eTables 7–9). Among a
subset of women who also received influenza immunization
Table 3
Birth outcomes by pertussis immunization status among delivering women in the US, 2010–2014.
Immunization timing Cases % Crude Adjusted IPTW
HR (95% CI) HR (95% CI) HR (95% CI)
Preeclampsia/Eclampsia None in pregnancy 40,930 4.40 – – – – – –
Optimal 5248 4.24 0.96 (0.94, 0.99) 0.90 (0.87, 0.93) 0.96 (0.94, 0.99)
Early 1096 4.38 1.00 (0.94, 1.06) 0.99 (0.93, 1.05) 1.05 (0.99, 1.12)
RR (95% CI) RR (95% CI) RR (95% CI)
Premature rupture of membranes None in pregnancy 43,485 4.67 – – – – – –
Optimal 7524 6.08 1.30 (1.27, 1.33) 1.08 (1.05, 1.11) 1.03 (1.00, 1.06)
Early 1418 5.66 1.21 (1.15, 1.28) 1.04 (0.99, 1.10) 1.08 (1.02, 1.15)
Chorioamnionitis None in pregnancy 25,149 2.70 – – – – – –
Optimal 4529 3.66 1.35 (1.31, 1.40) 1.14 (1.10, 1.18) 1.11 (1.07, 1.15)
Early 984 3.93 1.45 (1.37, 1.55) 1.23 (1.16, 1.31) 1.19 (1.11, 1.28)
Cesarean section None in pregnancy 305,882 32.88 – – – – – –
Optimal 37,900 30.62 0.93 (0.92, 0.94) 0.93 (0.92, 0.94)_ 0.95 (0.94, 0.96)
Early 7889 31.51 0.96 (0.94, 0.98) 0.97 (0.95, 0.98) 0.97 (0.95, 0.99)
Placental abruption None in pregnancy 7601 0.82 – – – – – –
Optimal 874 0.71 0.86 (0.81, 0.93) 0.82 (0.76, 0.89) 0.86 (0.80, 0.93)
Early 197 0.79 0.96 (0.84, 1.11) 0.93 (0.80, 1.07) 0.88 (0.73, 1.08)
Post-partum hemorrhage None in pregnancy 21,120 2.27 – – – – – –
Optimal 3814 3.08 1.36 (1.31, 1.40) 1.21 (1.17, 1.26) 1.23 (1.18, 1.28)
Early 829 3.31 1.46 (1.36, 1.56) 1.34 (1.25, 1.44) 1.34 (1.25, 1.44)
Abbreviations: IPTW, inverse probability of treatment weighting; HR, hazard ratio; CI, confidence interval; RR, risk ratio.
Models adjusted for: maternal age, delivery year, maternal hospitalizations and emergency department visits, other covered children on health insurance plan, US region,
residence in a Metropolitan Statistical Area, receipt of prenatal obstetric blood panel, ultrasound receipt, hypertension, diabetes, gestational diabetes, kidney dysfunction,
lupus, use of antihypertensives, use of antidiabetic medications, use of antidepressants, use of antibiotics. Postpartum hemorrhage also adjusted for: maternal chorioam-
nionitis, eclampsia, premature rupture of membranes, cesarean section, and placental abruption.
Table 4
Newborn outcomes by maternal immunization status among linked mother-newborn pairs in the US, 2010–2014.
Immunization timing Cases % Crude Adjusted IPTW
HR (95% CI) HR (95% CI) HR (95% CI)
NICU admission None in pregnancy 42,904 7.39 – – – – – –
Optimal 6996 7.25 0.98 (0.96, 1.01) 0.97 (0.95, 1.00) 1.00 (0.97, 1.03)
Early 1458 8.93 1.22 (1.16, 1.29) 0.93 (0.88, 0.98) 0.95 (0.89, 1.01)
Respiratory distress None in pregnancy 37,241 6.41 – – – – – –
Optimal 5739 5.94 0.93 (0.90, 0.95) 0.99 (0.96, 1.02) 0.97 (0.95, 1.00)
Early 1125 6.89 1.08 (1.02, 1.14) 0.91 (0.86, 0.97) 0.94 (0.88, 1.00)
Pulmonary hypertension None in pregnancy 1408 0.24 – – – – – –
Optimal 205 0.21 0.88 (0.76, 1.01) 0.85 (0.72, 1.00) 0.80 (0.67, 0.94)
Early 50 0.31 1.26 (0.95, 1.68) 0.99 (0.74, 1.32) 0.96 (0.68, 1.35)
Neonatal jaundice None in pregnancy 90,215 15.54 – – – – – –
Optimal 14,603 15.13 0.97 (0.96, 0.99) 1.06 (1.04, 1.08) 0.98 (0.97, 1.00)
Early 2562 15.70 1.01 (0.97, 1.05) 1.00 (0.97, 1.05) 0.94 (0.90, 0.98)
Encephalopathy None in pregnancy 577 0.10 – – – – – –
Optimal 135 0.14 1.41 (1.17, 1.70) 1.20 (0.97, 1.49) 1.01 (0.80, 1.28)
Early 30 0.18 1.85 (1.28, 2.67) 1.36 (0.93, 1.99) 0.94 (0.54, 1.61)
Seizures None in pregnancy 1607 0.28 – – – – – –
Optimal 261 0.27 0.98 (0.86, 1.12) 0.95 (0.82, 1.10) 1.06 (0.92, 1.21)
Early 75 0.46 1.67 (1.32, 2.10) 1.38 (1.08, 1.76) 1.18 (0.88, 1.59)
Neonatal sepsis None in pregnancy 13,187 2.27 – – – – – –
Optimal 1774 1.84 0.81 (0.77, 0.85) 0.83 (0.79, 0.88) 0.89 (0.84, 0.94)
Early 394 2.41 1.07 (0.97, 1.18) 0.89 (0.81, 0.99) 0.91 (0.81, 1.02)
Abbreviations: IPTW, inverse probability of treatment weighting; HR, hazard ratio; CI, confidence interval; NICU, neonatal intensive care unit.
Models adjusted for: maternal age, delivery year, maternal hospitalizations and emergency department visits, other covered children on health insurance plan, US region,
residence in a Metropolitan Statistical Area, receipt of prenatal obstetric blood panel, ultrasound receipt, hypertension, diabetes, gestational diabetes, kidney dysfunction,
lupus, use of antihypertensives, use of antidiabetic medications, use of antidepressants, use of antibiotics, premature delivery, postmature delivery, preeclampsia/eclampsia,
cesarean section, newborn sex, and meconium aspiration.during pregnancy (N = 239,593), overall rates of most safety events
were either very similar or slightly reduced compared to the overall
analyses (eTables 10–12). In many cases, the observed associations
between Tdap and outcomes were attenuated to the null, though
several RRs remained slightly elevated: optimally-timed Tdap, post-
partum hemorrhage, RR = 1.09 (95% CI: 1.03–1.16); and early Tdap,
premature rupture of membranes, RR = 1.11 (95% CI: 1.03–1.20),
and postpartum hemorrhage, RR = 1.18 (95% CI: 1.07–1.30). Among
the newborn outcomes, early Tdap was associated with seizures
[IPTW-weighted risks: 0.4% early immunized women, 0.3%
unimmunized women; RR = 1.50 (95% CI: 1.04–2.16)]; however,the number of cases was relatively small, translating into very small
absolute risk increases, and this increasewasnot observed in thepri-
mary analysis or in the optimally-vaccinated women.
4. Discussion
In this cohort of 1,079,034 pregnant women in the U.S., serious
maternal and infant adverse reactions following immunization
were rare; for example, only 1 of 207,857 immunized women
experienced anaphylaxis, and we detected no cases of GBS within
42 days after Tdap receipt. Twelve prenatally-vaccinated women
were later diagnosed with encephalopathy, although all cases
occurred during the delivery hospitalization or following delivery,
obscuring whether the encephalopathy was associated with the
immunization or with complications from the delivery itself. Also,
there were no increased risks in newborn outcomes associated
with maternal prenatal Tdap. However, we detected an increased
risk of mothers being diagnosed with chorioamnionitis and post-
partum hemorrhage associated with prenatal Tdap. Overall, the
risk of chorioamnionitis and postpartum hemorrhage were small,
2.8% and 2.4%, respectively, and these observed relative increases
do not translate to large overall absolute increases in birth compli-
cations. While Tdap was associated with slight reductions in the
risk of some outcomes, our primary purpose was to evaluate risks,
and we chose not to emphasize them.
The safety of prenatal Tdap has previously been evaluated by
smaller studies set in the UK or in smaller US regions. Our cross-
national US was larger than previous studies; additionally, we also
evaluated the timing of Tdap exposure. The current study both
confirmed an earlier-reported chorioamnionitis association and
reported a new association with post-partum hemorrhage. An ear-
lier British study did not demonstrate an association between post-
partum hemorrhage and prenatal Tdap [35], and among three prior
studies assessing chorioamnionitis and prenatal Tdap [18,36,37],
only one demonstrated an association; the largest examined
123,494 pregnancies in regional electronic health records, of which
21% received prenatal Tdap, and found RR = 1.19 (95% CI: 1.13–
1.26) for chorioamnionitis among women who received prenatal
Tdap, with chorioamnionitis diagnosed in 6.1% of immunized
women and 5.5% in unimmunized women, higher than our
national, claims-based IPTW-weighted risks of 3.3% in optimally-
immunized women and 3.0% of unimmunized women [18]. Our
primary analysis found an association similar in magnitude, how-
ever, these findings should be interpreted with caution; in sensitiv-
ity analyses of women who also received prenatal influenza
immunization and were therefore more similar in terms of health-
care access and behaviors, we did not observe an association
between Tdap and chorioamnionitis, and the post-partum hemor-
rhage association was attenuated to RR = 1.05 (95% CI: 0.99–1.10);
this suggests the potential for residual confounding by behavioral
or clinical factors uncaptured by claims. However, newborns
whose mothers received prenatal Tdap were not more likely to
experience any adverse outcomes, including NICU stays, respira-
tory distress, or neonatal sepsis, as compared to newborns of
unvaccinated mothers. Therefore, it does not appear that these
adverse birth outcomes, if indeed increased, had a clinically
relevant impact on newborns.
Immunization induces a short-lived nonspecific inflammatory
response [38], however, it is difficult to identify a biological
mechanism between this transient inflammatory response with
maternal adverse outcomes of postpartum hemorrhage or
chorioamnionitis which may occur weeks after immunization. As
such, the findings in our study should lead to further investigation.
When examining safety by the timing of Tdap administration,
early receipt was not associated with greater risks of the newborn
outcomes than optimal timing. Birth outcomes were also similar
between optimal and early Tdap receipt, but early receipt was asso-
ciated with an increased postpartum hemorrhage and chorioam-
nionitis risks, and additionally with a slightly increased risk of
premature rupture of membranes. The sensitivity analysis among
influenza immunization-receiving women demonstrated attenu-
ated associations with maternal adverse events, though the associ-
ations of early immunization with postpartum hemorrhage and
premature rupture of membranes persisted. Similar to our discus-
sion above, these results should be interpreted cautiously, as early
receipt of immunization prior to the recommended timing may be
indicative of atypical care or presumed fear of premature birth.Insurance claims provide longitudinal information across provi-
ders, and this very large cohort contains women from across the US
receiving care and delivering babies in a broad array of clinical
settings. However, there is potential for unmeasured confounding
as women receiving guideline-concordant immunizations may also
be receiving more thorough surveillance, detailed diagnoses,
and comprehensive care compared to women not receiving
recommended Tdap; our sensitivity analysis among influenza-
immunized women addressed this point, and found more attenu-
ated or null associations with adverse outcomes. Additionally,
the use of diagnosis coding for outcomes may result in misclassifi-
cation, yet we would not expect differential misclassification by
immunization status. The women in this study have employer-
sponsored commercial insurance, and thus our results may not
be generalizable to publically-insured or uninsured women. Gesta-
tional age is not available in insurance claims data; however, we
estimated gestational age at delivery from multiple sources,
including diagnosis information from both the mother and linked
newborns, where available. However, not all mothers successfully
linked to newborns who may be covered on different insurance
plans; although the characteristics of matching and non-
matching mothers were generally very similar, there may be resid-
ual inaccuracies in the gestational age estimation; therefore, we
chose to utilize broader timing categories (‘optimal’ or ‘early’) in
which we have greater confidence than a continuous estimate of
gestational age in weeks. For most comparisons, the IPTW and
multivariable adjusted models yielded similar results; yet there
were instances (typically with small numbers of outcomes) with
sizable differences in estimates (e.g. newborn encephalopathy,
early vs. none comparison), although the imprecision of the esti-
mates did not cause the conclusions to differ.
In conclusion, serious adverse events after Tdap receipt are rare,
and our study did not demonstrate an increased incidence of new-
born adverse events associated with Tdap. We did observe an
increased risk of chorioamnionitis consistent with a previous study
and novel findings of increased risk of postpartum hemorrhage
which warrants further investigation.Conflict of interest
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